Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $210,962 $(235,886)

Cost of sales adjustments 111,349 (1) 64,236 (1)

Research and development adjustments 8,013 (2) 41,500 (2)

Selling, general and administrative

adjustments 30,124 (3) -

Settlement reserve 7,450 (4) 425,000 (4)

Gain on sale of investment - (5,791) (5)

Gain on extinguishment of debt - (5,319) (6)

Interest expense adjustment 11,250 (7)

Restructuring charges 6,973 (8)

In-process research and development 10,000 (9)

Income tax adjustment (143,162) (10) (40,459) (10)

41,997 479,167

ADJUSTED NET INCOME $252,959 $243,281

BASIC ADJUSTED INCOME PER COMMON

SHARE $3.73 $3.66

DILUTED ADJUSTED INCOME PER COMMON

SHARE
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 ... sound therapy for tinnitus treatment. AudioNotch is pleased ... . With clinic locations in both British Columbia ... of audiology and hearing services. AudioNotch's tinnitus treatment ... , Upon entering a Destination Hearing clinic, patients ...
(Date:5/22/2013)... PA (PRWEB) May 22, 2013 Envera ... as Fermentation Manager. Mr. McErlean has an extensive ... of leadership positions throughout his career. , ... are very pleased to have Mike join our team”. ... installed large scale fermentation and downstream processing ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Through science ... and funds for lab equipment, 25 organizations will continue ... importance of optics and photonics in daily life with ... , The organizations, located in 10 countries, are the ... be awarded by SPIE, the international society for ...
Breaking Biology Technology:AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... 26 Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ... has received final approval from the,United States (U.S.) ... Drug Application (ANDA) for albuterol sulfate inhalation solution ... has been awarded 180,days of marketing exclusivity for ...
... Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced that ... inaugural companies in the new NASDAQ(R) NeuroInsights(R) Neurotech,Index. ... index designed to track,the performance of selected neurotechnology ... major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech Index ...
... Coggins to Continue as President and CSO, ... Ltd., a privately held biotechnology company developing,first-in-class Leukocyte ... the appointment of Jack M. Anthony to Chief,Executive ... position of,CEO will continue as President and assume ...
Cached Biology Technology:Watson Receives FDA Approval for Generic Accuneb(R) 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3Osprey Pharmaceuticals Names Jack M. Anthony as CEO 2Osprey Pharmaceuticals Names Jack M. Anthony as CEO 3
(Date:5/22/2013)... NEW YORK, May 22, 2013. Plastic additives known ... just about everywhere: They turn up in flooring, ... andaccording to the Centers for Disease Control and ... harmless, phthalates have come under increasing scrutiny. A ... phthalates (which can leech from packaging and mix ...
(Date:5/21/2013)... When infections occur in the body, stem cells ... multiplying and differentiating into mature immune cells that ... inflammation can deplete these cell populations, potentially leading ... as cancer. Now, a team of researchers led ... (Caltech) has found that, in mouse models, the ...
(Date:5/21/2013)... health stores, phosphatidylserine is a natural food supplement ... improve cognition and slow memory loss, it,s a ... Now a team headed by Prof. Gil Ast ... Department of Human Molecular Genetics have ... of genes involved in degenerative brain disorders, including ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 2
... May 11, 2010 For the first time in ... two-year decline in preterm birth rates, indicating that strategies implemented over ... the March of Dimes. "In 2003, we began a national ... baby deserves a healthy start in life," said Dr. Jennifer L. ...
... 2010 -- Investigators from around the country came to ... to share their knowledge of the burgeoning young field ... off proteins and have been implicated in viral infection, ... "The discovery that small RNAs could shut down ...
... May 11, 2010 -- Cancer uses devious means to ... way tumors express anti-cell death (anti-apoptotic) proteins to resist ... Medical Research Institute (Sanford-Burnham) has made two recent discoveries ... current treatments more effective. In a paper published ...
Cached Biology News:Federal report finds early births decline in most categories 2Researchers share insights into RNA 2Cancer: Trapping the escape artist 2
... ReadySub-Cell GT cell and PowerPac basic power supply ... nucleic acids in agarose gels. The mini format ... and electrodes, and leveling bubble. The PowerPac basic ... of 10-300 V, 4-400 mA, and 75 W. ...
... This CE-based system provides clear advantages ... (viral load, gene expression), mutation analysis, ... easy-to-use system with microplate connectivity is ... and quality control. The P/ACE ...
The imaging screen-K (Kodak), tritium, is a 20 x 25 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
Biology Products: